Nevanac

Nevanac is a brand name of nepafenac ophthalmic, approved by the FDA in the following formulation(s):

NEVANAC (nepafenac - suspension/drops; ophthalmic)

• 
  Manufacturer: ALCON PHARMS LTD
  
  Approval date: August 19, 2005
  
  Strength(s): 0.1% ^[RLD]

Has a generic version of Nevanac been approved?

No. There is currently no therapeutically equivalent version of Nevanac available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Nevanac. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Topically administrable compositions containing 3-benzoylphenylacetic acid derivatives for treatment of ophthalmic inflammatory disorders
  Patent 5,475,034
  Issued: December 12, 1995
  Inventor(s): Yanni; John M. & Graff; Gustav & Hellberg; Mark R.
  Assignee(s): Alcon Laboratories, Inc.
  Novel ester and amide derivatives of 3-benzoylphenylacetic acid are disclosed. The use of these novel derivatives and certain known derivatives in topically administrable compositions for the treatment of ophthalmic inflammatory disorders is also disclosed.
  
  Patent expiration dates:
  
  
  • June 6, 2014
    
    ✓ 
    Patent use: METHOD OF TREATING OCULAR INFLAMMATION
  
  



• 
  Topical nepafenac formulations
  Patent 7,834,059
  Issued: November 16, 2010
  Inventor(s): Wong; Warren
  Assignee(s): Alcon, Inc.
  Topical suspension compositions of nepafenac are disclosed. The compositions are especially suitable for topical ophthalmic administration.
  
  Patent expiration dates:
  
  
  • January 31, 2027
    
    ✓ 
    Patent use: METHOD OF TREATING OCULAR INFLAMMATION
  
  



• 
  Topical nepafenac formulations
  Patent 8,071,648
  Issued: December 6, 2011
  Inventor(s): Wong; Warren
  Assignee(s): Novartis AG
  Topical suspension compositions of nepafenac are disclosed. The compositions are especially suitable for topical ophthalmic administration.
  
  Patent expiration dates:
  
  
  • December 2, 2025
    
    ✓ 
    Drug product
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • August 19, 2010 - NEW CHEMICAL ENTITY
  
  

See also...

• Nevanac Consumer Information (Drugs.com)
• Nevanac Consumer Information (Wolters Kluwer)
• Nevanac Consumer Information (Cerner Multum)
• Nevanac Advanced Consumer Information (Micromedex)
• Nevanac AHFS DI Monographs (ASHP)
• Nepafenac Consumer Information (Drugs.com)
• Nepafenac Consumer Information (Wolters Kluwer)
• Nepafenac ophthalmic Consumer Information (Cerner Multum)
• Nepafenac Ophthalmic Advanced Consumer Information (Micromedex)
• Nepafenac AHFS DI Monographs (ASHP)